Minagar Milad, Alijanpour Ebrahim, Jabbari Ali, Rabiee Seyed Mozaffar, Banihashem Nadia, Amri Parviz, Mir Mehrafza, Hedayati Goodarzi Mohammad Taghi, Esmaili Mohammad
Department of Anesthesiology and Critical Care Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Department of Anesthesiology and Critical Care Medicine, Babol University of Medical Sciences, Babol, Iran.
Caspian J Intern Med. 2019 Spring;10(2):142-149. doi: 10.22088/cjim.10.2.142.
Spinal anesthesia is the common choice for anesthesia in lower abdomen surgery and intrathecal adjutants have gained popularity with the aim of prolonging the duration of block, quality of block and post operation pain control. The purpose of this study was to evaluate the effects of adding dexmedetomidine to hyperbaric bupivacaine in lower abdominal surgery under spinal anesthesia. The main outcomes were considered pain score, duration of analgesia, hemodynamic changes and adverse side effects like nausea and vomiting.
This double-blind randomized clinical trial was conducted on one hundred patients between 18 to 65 years old scheduled for lower abdominal surgery. Fifty patients were randomly allocated to receive either 12.5mg hyperbaric bupivacaine (2.5cc) plus 5µgr dexmedetomidine (0.5cc) intrathecally while fifty patients received either 12.5mg hyperbaric bupivacaine (2.5cc) and 0.5cc Saline 0.9% intrathecally.
Vital sign parameters like heart rate, blood pressure and oxygen saturation levels were registered in the normal range in both groups. The average duration of the onset of pain (230±86 min) in bupivacaine group was significantly (p≤0.000) less than dexmedetomidine group (495±138 minutes). The severity of pain at all times in dexmedetomidine group was significantly (p<0.05) less than bupivacaine group. The severity of shivering and the number of patients who needed treatment for nausea and vomiting in dexmedetomedine group has been less in comparison to bupivacaine.
We concluded that intrathecal dexmedetomidine increases the duration of analgesia and reduces postoperative pain without changes in the hemodynamic parameters and adverse side effects. It can be considered as an appropriate adjuvant to intrathecal local anesthetics for lower limb surgeries.
脊髓麻醉是下腹部手术麻醉的常用选择,鞘内辅助用药因旨在延长阻滞时间、提高阻滞质量和控制术后疼痛而受到欢迎。本研究的目的是评估在脊髓麻醉下的下腹部手术中,将右美托咪定添加到重比重布比卡因中的效果。主要观察指标为疼痛评分、镇痛持续时间、血流动力学变化以及恶心和呕吐等不良反应。
本双盲随机临床试验对100例计划进行下腹部手术的18至65岁患者进行。50例患者被随机分配接受鞘内注射12.5mg重比重布比卡因(2.5cc)加5µg右美托咪定(0.5cc),而另外50例患者接受鞘内注射12.5mg重比重布比卡因(2.5cc)和0.5cc 0.9%生理盐水。
两组的心率、血压和血氧饱和度水平等生命体征参数均在正常范围内。布比卡因组疼痛开始的平均持续时间(230±86分钟)显著(p≤0.000)短于右美托咪定组(495±138分钟)。右美托咪定组在所有时间点的疼痛严重程度均显著(p<0.05)低于布比卡因组。与布比卡因相比,右美托咪定组寒战的严重程度以及需要治疗恶心和呕吐的患者数量更少。
我们得出结论,鞘内注射右美托咪定可延长镇痛时间并减轻术后疼痛,而不改变血流动力学参数和不良反应。它可被视为下肢手术鞘内局部麻醉药的合适辅助药物。